Integrated Clinical Trial Services Introduces New Service
ICTS To Provide Study Information Websites
Raleigh, NC – Tom Sturgis, President of Integrated Clinical Trial Services (ICTS) announced that the firm has introduced a new service to provide Study Information Websites as part of a comprehensive patient services program. The Study Information Websites are third party verifiable information resources for individual clinical trials, permitting patients to look up specific information about the trial they are participating in and serving as a backup for other information sources. The Study Information Websites are web-optimized, and appear credible in the top 10 results of any search engine, resulting in additional patient recruitment as individuals search the web for information on their condition.
"We are pleased to be able to offer this new service as part of our comprehensive plan," said Sturgis. "It is important that patients have correct and valid information about their condition and can learn about opportunities to participate in clinical trials. We are excited to provide them with an additional source of knowledge."
About Integrated Clinical Trial Services:
Integrated Clinical Trial Services is a full service patient enrollment firm that provides clinical trial sponsors, contract research organizations and site networks with a comprehensive resource for patient recruitment expertise. The firm's services include patient enrollment feasibility, recruitment strategy, consulting, market research and protocol review, project management, concept design and production, media placement, community resource support, compliance and retention, and more. For more information please call (919) 388-3964. Integrated Clinical Trial Services can be found on the Internet at http://www.integratedtrials.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
